Although high-dose therapy with autologous hematopoietic stem cell transplantation (ASCT) is a widely used method of dose intensification in patients with hematological malignancies, patients aged over 60 are generally excluded. We evaluated high-dose therapy and ASCT in 29 cases involving 27 such patients (median age 63 years; range 61-68) with different malignancies. Patients were eligible if they had a good performance status, normal cardiac, respiratory, and hepatic function and a serum creatinine concentration of less than 2 mg/dl (Ͻ5 mg/dl in myeloma patients). Engraftment was assessable in 27 procedures. The median time to attain 0.5 and 1 × 10 9 PMN/l was 13 days (range 9-30) and 14 days (range 10-66), respectively. The median time taken to reach a platelet count greater than 50 × 10 9 /l was 14 days (range 8-223). Five patients (17%) died in the first 100 days after transplant, in two cases due to disease progression. The remaining three patients died as a consequence of transplant-related complications, with an overall transplant-related mortality of 10%. Five patients relapsed and died between 5 and 36 months after transplant. The remaining 17 patients are still alive without disease progression, with an actuarial overall survival of 47% at 42 months (95% CI 33-61). We consider that high-dose therapy with ASCT should be considered in those elderly patients with good performance status and without general organ impairment. Bone Marrow Transplantation (2001) 27, 21-25.
High-dose therapy with autologous hematopoietic stem cell transplantation (ASCT) is now a widely used method of dose intensification in patients with hematological and nonhematological malignancies. 1 However, most published series using ASCT have excluded patients aged over 60 years, probably due to an anticipated high rate of transplantrelated mortality (TRM) in these patients. In many neoplastic diseases the median age of patients is well over 60, [2] [3] [4] Correspondence: Dr MA Sanz so a large proportion are excluded as candidates for ASCT solely for reasons of age. Recently, reports of high-dose therapy followed by autologous blood stem cell transplantation (ABSCT) have shown reductions in TRM, when compared to historical reports of autologous bone marrow transplantation (ABMT). 5 This is an area of growing interest, and reports on the use of high-dose therapy and ASCT in patients over 60 have been published recently. [6] [7] [8] Some groups have suggested that age alone should not be considered an exclusion criterion for participation in treatments that include ASCT. 8 We have analyzed the results of high-dose therapy and ASCT in 27 patients Ͼ60 years with hematological malignancies, undergoing 29 ASCT procedures at our institution. Our preliminary data show the feasibility of the procedure, document rapid hematopoietic recovery and low TRM, as well as confirming ASCT as a valid therapeutic tool for elderly patients.
Patients and methods

Patient population
Between January 1 1991 and March 1 2000, 27 patients aged over 60 years with hematological malignancies underwent 29 ASCT procedures at the Bone Marrow Transplant Unit of the University Hospital, La Fe, Spain. Diagnoses were: multiple myeloma (MM: 11 cases); acute myeloblastic leukemia (AML: six cases); non-Hodgkin's lymphoma (NHL: four cases); breast carcinoma (BC: four cases); acute lymphoblastic leukemia (ALL: one case); and chronic myeloid leukemia (CML: one case). There were 13 males and 14 females. The median age at transplant was 63 years (range 61-68). Patient characteristics are listed in Table 1 .
Clinical status at transplant
Immediately before transplant, eight out of 11 patients with MM had responsive disease (five in PR and three in CR). Two had stable disease and there was one with progressive disease. Six AML patients were in CR (five in first CR and one in second CR) and two were in first relapse after an ABSCT. All the patients with BC underwent ASCT as adjuvant therapy, and patients with NHL were in first CR (two cases), relapse (one case) and first PR (one case). Finally, one patient with ALL and one patient with CML Bone Marrow Transplantation underwent transplantation in second CR and in the first chronic phase, respectively.
Source of stem cells
Peripheral blood was used as the source of stem cells in 26 cases. Two patients with AML in relapse after an ABSCT underwent a second autologous transplantation with the bone marrow harvested while in remission. Finally, one patient received peripheral blood and bone marrow due to the low number of peripheral blood progenitor cells (PBPC) collected.
Mobilization of peripheral blood progenitor cells
Mobilization procedures varied according to diagnosis and time of the study. Patients with multiple myeloma were mobilized either with G-CSF alone at a daily dose of 10 g/kg, for 4-5 days (three cases) or with intravenous cyclophosphamide (1.5 g/m 2 in a 2 h infusion) followed by G-CSF at a dose of 5 g/kg/day (eight cases). Patients with AML and CML underwent PBPC collection during the hematopoietic recovery period, after administration of a chemotherapy combination consisting of anthracycline and cytarabine, as previously described. 9, 10 In four cases, G-CSF was administered after chemotherapy. Finally, in the remaining nine patients, PBPC mobilization was carried out after G-CSF administration at a daily dose of 10 g/kg/day for 4-5 days.
PBPC collection has been extensively reported elsewhere. 9, 10 Briefly, for those patients undergoing mobilization with chemotherapy (with or without growth factors), aphereses were started when the absolute WBC count was Ͼ1 × 10 9 /l and the monocyte count was Ͼ20%. For those patients undergoing mobilization with growth factors alone, PBPC collections started when the CD34 + peripheral blood count was Ͼ20/l.
Conditioning regimens
Several preparative regimens were used throughout the study, according to the diagnosis of the patient and the institutional protocols used during the different periods of the study. Patients with acute leukemia received BUCY or BAVC as conditioning regimens as previously described. [9] [10] [11] Multiple myeloma patients received busulfan orally (4 mg/kg/day for 3 days) or total body irradiation (TBI) 3 Gy/day for 4 days followed by melphalan intravenously One patient with mantle cell lymphoma received i.v. cyclophosphamide (60 mg/kg/day, 2 days) followed by TBI (3 Gy/day, 4 days). The only patient with CML received BU orally (4 mg/kg/day, 4 days) alone as conditioning. Table 2 shows the different preparative regimens administered.
Supportive therapy
Patients were transplanted in single-patient, high-efficiency particulate air-filtered rooms. Supportive care included prophylactic cyprofloxacin (500 mg orally every 12 h), prophylactic acyclovir if positive for antibody to herpes simplex (250 mg/m 2 every 8 h), and oral fluconazole (100 mg/day). In cases of neutropenic fever, empiric broadspectrum antibiotic therapy was started immediately, with the combination of a beta-lactamic plus amikacin. Amphotericin B was given for suspected fungal infections. Growth factors were not routinely administered after transplant. Hemoglobin levels were maintained above 10 g/dl with packed red blood cells and platelets were transfused when less than 10 × 10 9 /l, or less than 20 × 10 9 /l in the case of fever. All cellular blood products were filtered and irradiated to 20 Gy before transfusion. Parenteral alimentation was given in case of severe mucositis.
Evaluation of toxicity
Monitoring of toxicity included evaluation of major sideeffects such as mucositis, signs of heart failure and other major organ dysfunction. Renal and liver function, coagulation parameters and electrolytes were tested every other day. All patients underwent daily full blood counts. Toxicity was graded according to Bearman et al's criteria. 12 
Eligibility criteria for transplant
Defined organ function criteria were used to select patients for ASCT. A selected patient was required to have an ECOG performance status of 0, 1 or 2; left ventricular ejection fraction greater than 45%; forced vital capacity and forced expiratory volume both greater than 50% predicted; serum creatinine concentration less than 2 mg/dl (Ͻ5 mg/dl in myeloma patients), and total bilirubin levels р2 mg/dl.
Statistical methods
The primary outcome for this study was TRM and overall survival (OS). Any death unrelated to relapse or disease progression during the first 120 days was considered as TRM (procedure-related death). Overall survival was defined as the time from the day of transplant until death from any cause. All patients had at least 2 months of follow-up evaluation before analysis. TRM and OS were estimated using the method of Kaplan and Meier. 13 All analyses were performed using the BMDP program. 14 
Results
PBPC and BM collection
The median number of apheresis collections per patient was three (range 1-6). For patients undergoing ABSCT the median number of CD34 + cells and CFU-GM collected was 6.75 × 10 6 /kg (range 0.58-145) and 22.5 × 10 4 /kg (range 0.05-254.5), respectively. In one patient with AML and a low CD34
+ CFU-GM count, bone marrow was harvested while in remission and infused with the PBPC. Finally, in the two patients undergoing ABMT the number of mononuclear cells administered was 0.43 and 3 × 10 8 /kg, respectively. 
Hematopoietic reconstitution and duration of hospitalization
Transplant-related morbidity and mortality
Mild or moderate mucositis was the toxicity most frequently seen. Severe mucositis was not observed. All patients developed severe marrow aplasia and neutropenic fever that required broad-spectrum antibiotics. Infection was microbiologically documented in nine cases (six with bacteremia), clinically documented in 10 (one with pneumonia) and possibly present in 10 patients. No patient developed veno-occlusive disease of the liver.
Five patients (17%) died in the first 100 days after transplant. Two patients had disease progression on days 47 and 86 and died shortly thereafter with active disease. The remaining three patients died from the consequences of transplant-related complications, with an overall TRM of 10%. According to the preparative regimen administered, two out of the three patients received melphalan followed by TBI or high-dose BU and the remaining patient received BAVC. The causes of death were cerebral hemorrhage (one case), interstitial pneumonia (one case), and bacterial pneumonia (one case).
Response and follow-up
Data concerning response relate to the 12 patients with active disease at the time of ASCT, excluding patients in CR. The two patients with NHL and measurable disease before transplant achieved CR after transplant. One of the two patients with relapsed AML achieved CR, and the other died due to transplant-related toxicity. Finally, six out of the eight patients with MM (five in PR and the patient with refractory disease) experienced improved clinical status after ASCT, achieving a plateau phase after transplant. 
Overall survival
Five patients relapsed and died between 5 and 36 months after transplant, while the remaining patients are still alive without disease progression. As of May 2000, 17 patients were alive in remission at a median of 38 months after transplant (range 2-74 months) with an actuarial OS of 47% at 42 months (95% CI 33-61). Figure 1 shows the OS of the whole series.
Discussion
We have examined the feasibility and results of ASCT in terms of TRM and OS in 27 patients with different hematological and non-hematological malignancies at our center. We chose to examine the outcome of patients aged over 60 years, since this has been the cut-off age for transplantation at our institution and at other centers in the past, due to concerns about an increased rate of toxicity in older patients. In our series, PBPC were collected with a reduced number of aphereses, and only two patients had a low PBPC count (measured as CFU-GM and CD34 + cells). This suggests that age by itself does not necessarily affect PBPC mobilization. Likewise, hematopoietic recovery after transplant was very similar to that usually observed in younger patients.
A number of series of ASCT procedures in elderly patients has been reported recently, with a TRM ranging from 0 to 11% (Table 3) . [6] [7] [8] 16 The TRM of our series is similar to that reported by other authors for this subgroup of patients, and compares favorably with that reported by the EBMT group (13% within 90 days of transplantation) in patients aged 55 years and over undergoing ABMT for intermediate-and high-grade NHL. 17 Thus, myeloablative therapy followed by ASCT could be an affordable procedure in older patients with an acceptable risk if the patients are carefully selected.
In this series, we selected most patients according to two criteria: good performance status and disease status, and general responsiveness to high-dose therapy. Regarding this, responses were observed in every patient with MM with only one transplant-related death. Although early reports suggested a lower event-free survival in elderly patients with MM, 18 other groups have shown that age is not an adverse parameter for MM patients undergoing ASCT. 19 ASCT in patients with MM up to 65 years of age is now widely used. 20 Currently, treatment of AML using myeloablative therapy followed by ASCT is widely used, although experience with this strategy in elderly patients is still limited. 4 In our series, we included six patients with AML, with only one procedure-related death, supporting the feasibility of the procedure. However, ASCT in AML patients Ͼ55 years of age has been associated with significant TRM in some series, generally much greater than that observed for younger patients. 21 This high TRM has been confirmed in a large series of patients recently reported by the EBMT group. 22 Thus, in cases of AML, stricter selection criteria should probably be applied to confirm this procedure as a risk-effective approach.
In conclusion, PBPC harvest is feasible in selected patients with different malignant diseases over 60 years of age. Likewise, TRM and hematological recovery are not significantly different from that observed in younger patients. Despite the small number of cases included in this series, this preliminary study demonstrates that ASCT can be safely performed in elderly patients, and there does not appear to be any biological reason to exclude patients over 60 from potentially curative therapy with ASCT. Thus, high-dose therapy with ASCT should be considered in those patients without general organ impairment and with good performance status. In our institution, the upper age limit for ASCT has been increased from 60 years in 1995 to 70 years in 2000.
